These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19764831)

  • 41. Malaria pigment and extracellular iron. Possible target for iron chelating agents.
    van Zyl RL; Havlik I; Hempelmann E; MacPhail AP; McNamara L
    Biochem Pharmacol; 1993 Apr; 45(7):1431-6. PubMed ID: 8471067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mode of action of iron (III) chelators as antimalarials: I. Membrane permeation properties and cytotoxic activity.
    Lytton SD; Mester B; Dayan I; Glickstein H; Libman J; Shanzer A; Cabantchik ZI
    Blood; 1993 Jan; 81(1):214-21. PubMed ID: 8417790
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Iron chelators: mode of action as antimalarials.
    Cabantchik ZI; Glickstein H; Golenser J; Loyevsky M; Tsafack A
    Acta Haematol; 1996; 95(1):70-7. PubMed ID: 8604590
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Iron chelators as drugs against malaria pose a potential risk.
    Golenser J; Domb A; Leshem B; Kremsner P; Luty A
    Redox Rep; 2003; 8(5):268-71. PubMed ID: 14962362
    [No Abstract]   [Full Text] [Related]  

  • 45. Iron chelation therapy for malaria: a review.
    Mabeza GF; Loyevsky M; Gordeuk VR; Weiss G
    Pharmacol Ther; 1999 Jan; 81(1):53-75. PubMed ID: 10051178
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aminothiol multidentate chelators as antimalarials.
    Loyevsky M; John C; Zaloujnyi I; Gordeuk V
    Biochem Pharmacol; 1997 Aug; 54(4):451-8. PubMed ID: 9313771
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identifying a Deferiprone-Resveratrol Hybrid as an Effective Lipophilic Anti-Plasmodial Agent.
    Maneekesorn S; Chuljerm H; Koonyosying P; Uthaipibull C; Ma Y; Srichairatanakool S
    Molecules; 2021 Jul; 26(13):. PubMed ID: 34279413
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis and antimalarial activity of amide and ester conjugates of siderophores and ozonides.
    Tiwari R; Checkley L; Ferdig MT; Vennerstrom JL; Miller MJ
    Biometals; 2023 Apr; 36(2):315-320. PubMed ID: 35229216
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, synthesis, and study of a mycobactin-artemisinin conjugate that has selective and potent activity against tuberculosis and malaria.
    Miller MJ; Walz AJ; Zhu H; Wu C; Moraski G; Möllmann U; Tristani EM; Crumbliss AL; Ferdig MT; Checkley L; Edwards RL; Boshoff HI
    J Am Chem Soc; 2011 Feb; 133(7):2076-9. PubMed ID: 21275374
    [TBL] [Abstract][Full Text] [Related]  

  • 50. From one Nobel Prize (P. Ehrlich) to another (Tu Youyou): 100 years of chemotherapy of infectious diseases.
    Cabantchik ZI; Drakesmith H
    Clin Microbiol Infect; 2016 Mar; 22(3):213-4. PubMed ID: 26673734
    [No Abstract]   [Full Text] [Related]  

  • 51. Malaria in Kenya's western highlands.
    Shanks GD; Hay SI; Omumbo JA; Snow RW
    Emerg Infect Dis; 2005 Sep; 11(9):1425-32. PubMed ID: 16229773
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Iron availability and infection.
    Weinberg ED
    Biochim Biophys Acta; 2009 Jul; 1790(7):600-5. PubMed ID: 18675317
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antimalarial drug resistance - You have been 'WWARN-ed'!
    Chiodini J
    Travel Med Infect Dis; 2019; 27():140-142. PubMed ID: 30641131
    [No Abstract]   [Full Text] [Related]  

  • 54. Deferoxamine effects on Plasmodium falciparum gene expression.
    Moormann AM; Hossler PA; Meshnick SR
    Mol Biochem Parasitol; 1999 Jan; 98(2):279-83. PubMed ID: 10080396
    [No Abstract]   [Full Text] [Related]  

  • 55. 2015: Signaling Breakthroughs of the Year.
    Adler EM
    Sci Signal; 2016 Jan; 9(409):eg1. PubMed ID: 26732760
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The many faces of the adamantyl group in drug design.
    Liu J; Obando D; Liao V; Lifa T; Codd R
    Eur J Med Chem; 2011 Jun; 46(6):1949-63. PubMed ID: 21354674
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antimalarial action of hydroxamate-based iron chelators and potentiation of desferrioxamine action by reversed siderophores.
    Golenser J; Tsafack A; Amichai Y; Libman J; Shanzer A; Cabantchik ZI
    Antimicrob Agents Chemother; 1995 Jan; 39(1):61-5. PubMed ID: 7695330
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Iron chelators as anti-infectives; malaria as a paradigm.
    Cabantchik ZI; Moody-Haupt S; Gordeuk VR
    FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):289-98. PubMed ID: 10575141
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bark, weeds, and iron chelators--drugs for malaria.
    Wyler DJ
    N Engl J Med; 1992 Nov; 327(21):1519-21. PubMed ID: 1406884
    [No Abstract]   [Full Text] [Related]  

  • 60. In vivo antimalarial action of a lipophilic iron (III) chelator: suppression of Plasmodium vinckei infection by reversed siderophore.
    Lytton SD; Loyevsky M; Mester B; Libman J; Landau I; Shanzer A; Cabantchik ZI
    Am J Hematol; 1993 Jul; 43(3):217-20. PubMed ID: 8352239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.